UCB and Ariceum Therapeutics sign a Strategic Research Collaboration to Discover New Modalities for the Treatment of Immune-related Diseases and Cancer UCB s. | May 11, 2023
UCB's expertise in macrocyclic peptide discovery, using its proprietary mRNA-display platform, ExtremeDiversity, will aid Ariceum's discovery of treatments for solid tumorsAriceum's expertise
UCB and Ariceum have announced a strategic research collaboration to identify and develop systemic targeted radiopharmaceuticals for the treatment of solid tumors and immune-related diseases.
UCB and Ariceum Therapeutics sign a Strategic Research Collaboration to Discover New Modalities for the Treatment of Immune-related Diseases and CancerUCB’s expertise in macrocyclic peptide discovery, using its proprietary mRNA-display platform, ExtremeDiversity™, will aid Ariceum’s discovery of tr.